Track Acurx Pharmaceuticals's net income ($-10B) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
Loading...
Loading...
Acurx Pharmaceuticals (ACXP) currently reports a net income of $-10B as of June 2026. That compares with $-5.1B in the prior-year period — down 96.3% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Acurx Pharmaceuticals's net income history and peer comparisons.
Acurx Pharmaceuticals's net income decreased from $-5.1B to $-10B — a 96.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Acurx Pharmaceuticals's net income of $-10B is lower than the Healthcare sector average of $16B. That is roughly 162.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Acurx Pharmaceuticals reported $-10B in net income as of June 2026. That compares with $-5.1B in the prior-year period — down 96.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current net income of $-10B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Acurx Pharmaceuticals, and consider following ACXP for alerts when major investors trade the stock.